-
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
•
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with US pharmaceutical major Eli Lilly & Co., (NYSE: LLY), aimed at accelerating the global clinical development of Laekna’s obesity treatment candidate, LAE102. Under the terms of the agreement, Lilly will take on the responsibility for…
-
Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
•
Eli Lilly and Company (NYSE: LLY), a leading US pharmaceutical corporation, has announced positive results from the Phase III SUMMIT study assessing the effects of tirzepatide in heart failure. The study successfully met both primary endpoints, marking a significant advancement in the treatment of heart failure. Study Outcomes and EfficacyTirzepatide,…
-
Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
•
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced positive results from a Phase II study for its investigational drug, muvalaplin, a selective lipoprotein(a) [Lp(a)] inhibitor. The study successfully met its primary endpoint, showing a significant reduction in elevated Lp(a) levels in adults, a genetic risk…
-
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from its Phase III SURMOUNT-1 study for tirzepatide, marking the longest completed study to date for the dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This data provides significant insights into the drug’s…
-
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20 million milestone payment from its Japanese partner Takeda (TYO: 4502; NYSE: TAK), following the achievement of over USD 200 million in sales of Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC). Fruquintinib, a selective oral inhibitor…
-
Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
•
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for the third quarter of 2024, with total revenues increasing by 20% year-on-year (YOY) to USD 11.439 billion. The growth was propelled by volume increases from Mounjaro and Zepbound, as well as higher realized prices. In…
-
Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment
•
Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of Health for its Mounjaro (tirzepatide) in KwikPen presentation, marking a significant step in the treatment of weight management and type 2 diabetes. Mounjaro is indicated for adults with obesity (BMI of 30 kg/m^2 or greater)…
-
Eli Lilly’s Ebglyss Shows Positive Results in Phase III Study for Atopic Dermatitis Patients Previously Treated with Dupilumab
•
Eli Lilly & Co. (NYSE: LLY), a leading U.S. pharmaceutical company, has announced the results of the Phase III Adapt study for its interleukin-13 (IL-13) inhibitor, Ebglyss (lebrikizumab). The study demonstrated that Ebglyss improved skin conditions, including on the hands and face, and reduced itch in patients with moderate-to-severe atopic…
-
Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain
•
Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in Great Britain for Kisunla (donanemab), an Alzheimer’s disease (AD) treatment. Kisunla is an intravenous infusion administered every four weeks to eligible adults with mild cognitive impairment and mild dementia due to AD. Eligibility is restricted…
-
Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced the opening of the Lilly China Medical Innovation Center in Beijing, China, along with plans to establish a Lilly Gateway Labs (LGL). These initiatives are aimed at enhancing clinical trials and bolstering drug research and…
-
BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
•
BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166), a Chinese biopharmaceutical company, has announced positive results from the Phase II clinical study (CTR20233198) for its investigational drug BGM0504. This dual agonist targets GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulin stimulating polypeptide) receptors and is being studied for the treatment of…
-
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
•
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated…
-
Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform
•
Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience AG, a subsidiary of Danish biotech Nordic Bioscience, to advance the development of Dual Amylin Calcitonin Receptor Agonists (DACRA). This new class of potential treatments targets obesity and related disorders, marking a significant step in…
-
Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand
•
Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5 billion (USD 211.95 million) to expand its manufacturing capabilities in Suzhou, a strategic move aimed at augmenting the production of drugs for type 2 diabetes and obesity. This capital expenditure is set to not only…
-
Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit
•
Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE: LLY) China as the vice president of the diabetes products business unit. She will report directly to Huzur Devletsah, the president and general manager of Lilly China. Yan Qiong brings nearly two decades of experience…
-
Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives
•
Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc., as its first chief AI officer, effective from October 21, 2024. Fuchs will be responsible for providing strategic direction and leadership for AI initiatives across the company, including drug discovery, clinical trials, manufacturing, and commercial…
-
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
•
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC candidate, Rina-S, as registered on ClinicalTrials.gov on October 1, 2024. The trial aims to enroll 530 patients with platinum-resistant advanced ovarian cancer to compare Rina-S head-to-head with chemotherapy, with an anticipated preliminary completion date in…
-
Yabao Pharmaceutical’s SY-009 Receives NMPA Approval for Phase II Clinical Trial in Constipation
•
Yabao Pharmaceutical Group Co., Ltd (SHA: 600351), a Chinese pharmaceutical company, has announced that SY-009 capsules, a sodium-glucose linked transporter-1 (SGLT-1) inhibitor co-developed with Eli Lilly & Co., (NYSE: LLY) have received approval from the National Medical Products Administration (NMPA) to proceed to a Phase II clinical study for the…
-
Eli Lilly’s Kisunla Secures Market Approval in Japan for Early Symptomatic Alzheimer’s
•
Eli Lilly & Co. (NYSE: LLY) has announced that its Alzheimer’s disease (AD) treatment, Kisunla (donanemab), has been granted market approval in Japan. The drug is indicated for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and/or mild dementia stage, who have confirmed amyloid pathology. Kisunla…
-
Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA
•
Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from the US Food and Drug Administration (FDA) for Ebglyss (lebrikizumab), a new treatment for adults and children aged 12 years and over suffering from moderate-to-severe atopic dermatitis (AD). Ebglyss is an interleukin-13 (IL-13) inhibitor that…
-
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has entered into a research collaboration with Genetic Leap, a U.S. biotech firm specializing in artificial intelligence (AI) and RNA genetic medicine. This partnership expands on a previously successful pilot and will see Genetic Leap apply…
-
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
•
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked on a drug discovery partnership with Switzerland’s Haya Therapeutics, a move that underscores its commitment to advancing its anti-obesity portfolio. The collaboration will tap into Haya’s cutting-edge expertise in the dark genome, the largely non-protein-coding…
-
Manufacturing Challenges for Novo Nordisk’s Ozempic Impact Diabetes and Obesity Treatments in Europe
•
Novo Nordisk (NYSE: NVO), a leading Danish pharmaceutical company, has released a joint statement with the European Medicines Agency (EMA) addressing the ongoing supply challenges for its GLP-1 receptor agonist, Ozempic (semaglutide). The statement cites increased demand and manufacturing site capacity constraints as the primary factors contributing to the shortages,…
-
Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
•
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport area, marking a significant expansion in its research capabilities. The Lilly Seaport Innovation Center (LSC) spans 346,000 square feet and will accommodate 500 researchers, alongside 200 personnel involved in Lilly’s incubator initiative, Lilly Gateway Labs.…
-
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
•
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has reported robust growth in its Q2 2024 financials, highlighting that previous manufacturing capacity constraints affecting its glucagon-like peptide-1 (GLP-1) drugs have been resolved. The company’s global sales growth surged 37% year-on-year (YOY) in constant currency…
-
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced that it has received a new market approval from the National Medical Products Administration (NMPA) in China for its drug Mounjaro (tirzepatide) as a long-term weight management treatment. Administered as a once-weekly injection, Mounjaro is…
-
Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial
•
Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline with the failure of the Phase II trial for LY3361237, an antibody agonist targeting the BTLA immune checkpoint, in the treatment of systemic lupus erythematosus (SLE). The trial, registered on clinicaltrials.gov as NCT05123586, was terminated…
-
Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2…
-
Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval
•
Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for donanemab as a treatment for adults with early symptomatic Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI) and individuals with mild AD-related dementia, confirmed to have amyloid pathology.…
-
Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has entered into a strategic partnership with fellow US firm Radionetics Oncology to gain access to Radionetics’ pipeline of innovative small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals. Under the terms of the agreement, Lilly…
-
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
•
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious market launch for the anti-obesity drug Wegovy (semaglutide) in China following its recent approval. The strategy is aimed at preserving manufacturing capacity and maintaining the stability of global supply chains, according to Maziar Mike Doustdar,…
-
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial…
-
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
•
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000 shares of AbbVie Inc. (NYSE: ABBV) at a price below market value, according to an announcement from the pharmaceutical company last week. AbbVie has made it clear that it does not endorse Tutanota’s offer and…
-
Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment
•
The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly & Co. (NYSE: LLY) for its Baqsimi (glucagon nasal powder spray), marking a significant advancement in the treatment of severe hypoglycemia in diabetic patients aged four and above. Hypoglycemia, a common and potentially dangerous complication of…
-
Eli Lilly’s Tirzepatide Hits Primary Endpoint in MASH Trial, Outperforming Placebo
•
Eli Lilly and Company (NYSE: LLY), a global healthcare conglomerate, has announced positive outcomes from a Phase II clinical trial of tirzepatide, a novel GIP/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. The study successfully achieved its primary endpoint, demonstrating resolution of MASH without exacerbation of…
-
FDA Committee Backs Eli Lilly’s Donanemab for Early Symptomatic Alzheimer’s Disease
•
This week, a US Food and Drug Administration (FDA) advisory committee endorsed the safety and efficacy of Eli Lilly and Co.’s (NYSE: LLY) donanemab, a biologic therapy that targets amyloid plaques, for its use in treating early symptomatic Alzheimer’s disease (AD). The recommendation follows a request from the regulator earlier…
-
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
•
QuantumPharm Inc., operating under the name Xtalpi Inc., has successfully conducted an initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.13 billion (USD 144.5 million). The shares of Xtalpi, listed under the ticker symbol 02228, were priced at HKD 6.03 per share. Xtalpi is a pioneer…
-
Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases
•
Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization rights to a portfolio of UNC13A-targeting compounds from QurAlis, a biopharmaceutical company based in the U.S. The portfolio includes the antisense oligonucleotide (ASO) QRL-204, which is considered a potential best-in-class candidate for treating neurodegenerative diseases…
-
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
•
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical trial for its KRAS inhibitor, olomorasib, in patients with KRAS G12C-mutant advanced solid tumors. The trial also explores the combination of olomorasib with Merck, Sharp & Dohme’s (MSD; NYSE: MRK) top-selling checkpoint inhibitor, Keytruda (pembrolizumab),…
-
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
•
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced the launch of a new formula for Taltz (ixekizumab) in China, following its approval in the country in November of the previous year. The new formula of the IL-17A monoclonal antibody (mAb) is free from…
-
Eli Lilly Invests $5.3 Billion to Expand Manufacturing Capacity for Incretin Receptor Agonists
•
Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion aimed at boosting its manufacturing capacity for incretin receptor agonists Zepbound (tirzepatide) and Mounjaro (tirzepatide). This initiative involves the expansion of an active pharmaceutical ingredients (APIs) manufacturing facility in the United States. With this investment,…
-
Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals
•
Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a US-based developer of anticancer radiopharmaceuticals, to co-develop first-in-class treatments for solid tumors and diagnostic products. Under the terms of the agreement, Aktis is set to receive an upfront payment of USD 60 million, a significant…
-
Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment
•
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it has received its first market approval from the National Medical Products Administration (NMPA) in China for Mounjaro (tirzepatide). The drug is indicated for the treatment of type 2 diabetes mellitus (T2DM) in patients who have…
-
Eli Lilly’s Weekly Insulin Efsitora Alfa Matches Daily Basal Insulins in Reducing A1C Levels
•
Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a comparative study on its once-weekly insulin efsitora alfa. The study demonstrated that efsitora alfa is non-inferior in reducing A1C levels compared to daily basal insulins degludec or glargine in adults with type 2 diabetes (T2D).…
-
Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China
•
Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion of its clinical partnership with Shanghai East Hospital, a Class 3A general hospital in China. This strategic collaboration aims to address the increasing demand for clinical studies within the country. The two entities initially collaborated…
-
Innovent Biologics’ Mazdutide Shows Superiority in Type 2 Diabetes Phase III Trial
•
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that its Phase III DREAMS-2 study for mazdutide (IBI362), a dual agonist targeting both glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), has met its primary endpoint in Chinese subjects with type 2 diabetes (T2D). The…
-
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
•
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of 2024 that exceeded expectations, with sales up 26% year-on-year (YOY) to USD 8.77 billion. The growth was driven by the strong performance of the weight-loss drug Mounjaro (tirzepatide), diabetes therapy Zepbound (tirzepatide), Jardiance (empagliflozin) for…
-
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
•
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity” bill proposal that could have significant implications for the biotechnology industry. The bipartisan-supported bill aims to prohibit companies receiving US government funding from engaging in commercial dealings with certain biotech companies identified as national security…
-
Roche and Eli Lilly’s Elecsys pTau217 Blood Test Earns FDA Breakthrough Designation for Alzheimer’s Detection
•
The U.S. Food and Drug Administration (FDA) has granted a breakthrough device designation for Elecsys pTau217, a blood test co-developed by Roche (SWX: ROG) and Eli Lilly (NYSE: LLY), aimed at detecting amyloid pathology, a hallmark of Alzheimer’s disease. This designation is significant in the context of the growing global…
-
AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion
•
AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion Pharmaceuticals (NASDAQ: FUSN), a Canada-based developer of radioconjugate (RC) therapies, in a deal valued at up to USD 2.4 billion, including upfront and potential contingent value payments. The acquisition is expected to be finalized in…
-
Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market
•
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide) take the lead in total US prescriptions over its competitor Eli Lilly’s (NYSE: LLY) Zepbound (tirzepatide), according to Reuters. Despite this, Zepbound has seen more new prescriptions filled, indicating a close competition in a market…
-
Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review
•
Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s disease candidate, donanemab, with the U.S. Food and Drug Administration (FDA) pushing the timeline beyond the fourth quarter of 2024. The delay follows the FDA’s request for an advisory committee meeting to evaluate donanemab’s Phase…
-
Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024
•
Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20% year-on-year (YOY) increase in revenue, reaching USD 34.1 billion, as detailed in their Q4 2023 report released this week. This growth was substantially driven by the company’s metabolism drugs, indicating a recovery from the COVID-19…
-
Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss
•
Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by its subsidiary Akouos for gene therapy AK-OTOF, which is being investigated for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF). The press release reported that the first participant in…
-
Eli Lilly’s Olumiant Patent Invalidated in China, Generic Version Approved
•
The China National Intellectual Property Administration (CNIPA) has declared the compound patent CN200980116857.7 for Eli Lilly’s (NYSE: LLY) JAK inhibitor Olumiant (baricitinib) invalid in its entirety, as per a recent public document. The decision came after a challenge from Nanjing SiPake Pharmaceutical Technology Co., Ltd. Baricitinib, a JAK1/JAK2 inhibitor originally…
-
Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis
•
Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its generic version of Eli Lilly Inc (NYSE: LLY)’s Forteo (teriparatide) injection, indicated for the treatment of osteoporosis in postmenopausal women who are at…
-
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
•
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ: GOOGL), has entered into its inaugural pharmaceutical collaborations, signing separate agreements with Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). These partnerships are aimed at discovering small-molecule therapeutics for multiple undisclosed targets. Under the terms…
-
Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China
•
Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA) for Emgality (galcanezumab) as a preventive treatment for migraines in adults. Emgality, a monoclonal antibody that selectively targets calcitonin gene-related peptide (CGRP), was initially approved by the U.S. FDA in September 2018 for migraine prevention…
-
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
•
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company has no plans to develop a competing product in the GLP-1 drug market, dominated by Novo Nordisk (CPH: NOVO-B) and Eli Lilly (NYSE: LLY), despite significant demand. However, Houman Ashrafian, head of R&D, indicated that…
-
Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm
•
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced that Huzur Devletsah has officially assumed the role of president and general manager of its China operations, marking a historic moment as she becomes the first female leader of the unit. Huzur Devletsah’s journey with…
-
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
•
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first patient dosing in the Phase III GLORY-2 study, which is assessing the higher dose 9mg version of mazdutide (IBI362) for the treatment of obesity in Chinese adults. Mazdutide is a dual agonist drug candidate targeting…
-
Eli Lilly Teams Up with Fauna Bio to Uncover New Anti-Obesity Drug Targets
•
Eli Lilly (NYSE: LLY) has entered a collaboration agreement with fellow U.S. firm Fauna Bio to explore novel anti-obesity drug targets, marking a significant step in the competitive weight-loss therapies market. The financial terms of the deal include an undisclosed upfront payment, potential sales royalties, and up to $494 million…
-
Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
•
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT) this week, following the clearance of the last regulatory requirement last month. As part of the acquisition, Lilly gains access to Point’s PNT2002, a PSMA-targeting radiopharmaceutical currently in Phase III trials for metastatic castration-resistant prostate…
-
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
•
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a clinical-stage developer of actinium-based radiopharmaceutical therapeutics (RPT), bolstering its oncology portfolio. BMS will purchase all outstanding shares of RayzeBio for an estimated $4.1 billion, with the transaction anticipated to close in the first half of…
-
Jiangsu Hengrui Medicine Wins NMPA Approvals for SLE and Lymphoma Drug Candidates
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that it has received separate clinical trial approvals from China’s National Medical Products Administration (NMPA) for two of its drug candidates, SHR0302 and SHR2554. SHR0302 is anticipated to treat systemic lupus erythematosus (SLE), while SHR2554 is…
-
Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market
•
Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and Rayvow (lasmiditan) from U.S. partner Eli Lilly (NYSE: LLY) for the European market. Under the agreement, Lilly will receive an upfront payment of $50 million, along with milestone payments, pending regulatory approval expected in Q1…
-
Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma
•
Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, according to the China Center for Drug Evaluation (CDE) website. The application targets adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously undergone BTK inhibitor…
-
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech firm Carmot Therapeutics, a specialist in anti-obesity and diabetes drugs, in a transaction valued at USD 2.7 billion with potential milestone payments of up to USD 400 million. The acquisition is expected to close in…
-
Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia
•
The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated approval for its reversible BTK inhibitor Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults who have received at least two prior lines of therapy. This regulatory…
-
Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market
•
Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its generic version of Eli Lilly’s (NYSE: LLY) recombinant peptide Forteo (teriparatide), both of which are indicated for the treatment of osteoporosis. The subcutaneous injection will be marketed in partnership with Apotex. According to the public…
-
Perpetual Medicines Launches with $8 Million Seed Round, Led by Chengwei Capital
•
Perpetual Medicines, a biotech firm with operations in Shanghai and Boston, has officially launched, announcing an $8 million seed financing round led by Chengwei Capital. The company has appointed Dr. Kerry Blanchard as co-founder and CEO, following his recent departure from Everest Medicines in August. Perpetual aims to develop an…
-
Eli Lilly Partners with Prism BioLab to Discover Peptide-Mimicking Small Molecule Inhibitors
•
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with Japan-based biotechnology firm Prism BioLab to discover peptide-mimicking small molecule inhibitors (SMIs) for up to three protein-protein interaction (PPI) targets. Under the agreement, Lilly will be responsible for the clinical development and commercialization of any successful candidates, while…
-
Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance (empagliflozin), has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult chronic kidney disease (CKD). This development expands the drug’s therapeutic applications in China. EMPA-KIDNEY Study Outcomes The approval…
-
Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval from the National Medical Products Administration (NMPA) for their SGLT2 inhibitor Jardiance (empagliflozin) aimed at treating adult chronic kidney disease (CKD). This pivotal approval marks a significant advancement in the management of CKD, further establishing…
-
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
•
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer of a radioactive materials license from Point Biopharma (NASDAQ: PNT) to Eli Lilly (NYSE: LLY). This decision marks the final regulatory clearance necessary for Eli Lilly’s acquisition of Point Biopharma, which was announced last month.…
-
Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY) donanemab is set to receive priority review status for the treatment of early-stage Alzheimer’s disease (AD). This development is significant as it pertains to the drug’s potential use in patients with mild cognitive impairment or…
-
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
•
It has been reported that Benjamin L. Basil, the current president and general manager of Eli Lilly (NYSE: LLY) China, will be leaving his position and the country for personal reasons. This change comes after Basil assumed the role in September 2022, succeeding Julio Gay-Ger. Background and AchievementsBasil’s tenure at…
-
Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults
•
Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration (FDA) for its once-weekly injection Zepbound (tirzepatide). The drug is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight conditions, including those with at least one…
-
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
•
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio…
-
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
•
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I clinical study for its YR001 external preparation in the United States. The topical ointment, which is a small molecule Kv1.3 inhibitor, showed a good safety and tolerability profile in all subjects tested. YR001: Indications and…
-
Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
•
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE: LLY) for its interleukin-23p19 antagonist, Omvoh (mirikizumab), as a treatment for moderately to severely active ulcerative colitis (UC) in adults. This approval is a significant milestone for Eli Lilly, expanding its portfolio in the inflammatory…
-
Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio
•
US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink Bioscience, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). This strategic move is set to enhance Eli Lilly’s capabilities in developing innovative oncology treatments through Mablink’s advanced ADC technology. Mablink’s Proprietary ADC TechnologyMablink Bioscience’s…
-
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
•
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating its GLP-1 receptor agonist, tirzepatide, in adults with obesity or overweight accompanied by comorbidities, excluding type 2 diabetes (T2D). The study successfully met its two co-primary endpoints, demonstrating superiority over placebo in weight loss after…
-
Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4
•
Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on KRAS and Nectin-4, all of which are currently in the pre-clinical stage. This strategic move highlights Lilly’s commitment to advancing cancer therapies that target specific oncogenic pathways. Details of the New Oncology Programs The new…
-
FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment
•
The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for lebrikizumab, an anti-IL-13 biologic intended for the treatment of moderate-to-severe atopic dermatitis. The company announced the setback this week, highlighting the challenges faced in the regulatory approval process. Background on Lebrikizumab’s Acquisition Eli Lilly acquired…
-
Eli Lilly’s Insulin Biosimilar YouBiAn Approved for Diabetes Treatment in China
•
US pharmaceutical major Eli Lilly (NYSE: LLY) has announced that it has received market approval from the National Medical Products Administration in China for its insulin glargine product, YouBiAn. This treatment is indicated for adults with type 1 or type 2 diabetes requiring insulin therapy, as well as for children…
-
United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment
•
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its Category 1 drug candidate, UBT251, for the treatment of overweight and obesity. UBT251: A Triple Agonist…
-
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US Food and Drug Administration (FDA) for their SGLT2 inhibitor, Jardiance (empagliflozin), marking a significant advancement in the treatment of chronic kidney disease (CKD). The drug is now approved for the prevention of kidney function decline,…
-
Eli Lilly Sues US Sellers of Counterfeit Mounjaro Products
•
Pharmaceutical giant Eli Lilly (NYSE: LLY) has filed a lawsuit in the United States against medical spas, wellness centers, and compounding pharmacies that are selling unregistered products claiming to be Mounjaro (tirzepatide), the company’s GLP-1 agonist. Mounjaro has recently gained popularity for its off-label use as a weight-loss drug, prompting…
-
Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors
•
Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to clinically develop Boundless’s CHK1-targeting small-molecule inhibitor (SMI) BBI-355 in combination with Lilly’s CDK4/6 inhibitor Verzenio (abemaciclib). This collaboration aims to target locally advanced or metastatic solid tumors with oncogene amplifications, with Boundless highlighting its candidate…
-
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
•
Innovent Biologics (HKEX: 01801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly & Co. (Nasdaq: LLY), a titan of the US pharmaceutical industry, have jointly declared a significant milestone in the Phase II clinical study known as ORIENT-2. The study focuses on the co-developed anti-programmed death-1 (PD-1)…
